Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Magli

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Stem Cell Reports|August 5, 2022
Dual inhibition of MAPK and PI3K/AKT pathways enhances maturation of human iPSC-derived cardiomyocytesBayardo I Garay, Sophie Givens, Phablo Abreu, et al.
Acta Oncologica (Stockholm, Sweden)|October 6, 2023
Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivorsSofia Spampinato, Tiziana Rancati, Justyna Magdalena Waskiewicz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 27, 2021
Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort studyAndrea Bresolin, Adriana Faiella, Elisabetta Garibaldi, et al.
Stem Cell Reports|January 11, 2023
Dual inhibition of MAPK and PI3K/AKT pathways enhances maturation of human iPSC-derived cardiomyocytesBayardo I Garay, Sophie Givens, Phablo Abreu, et al.
European Urology Oncology|December 16, 2025
Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation TherapyFederico Mastroleo, Riccardo Villa, Mattia Zaffaroni, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 2024
Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiationGiuseppe Sanguineti, Maddalena Pavarini, Fernando Munoz, et al.
European Urology|June 24, 2023
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter StudyFelix Preisser, Raisa S Abrams-Pompe, Piter Jan Stelwagen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 4, 2025
Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrenceFederica Ferrario, Ciro Franzese, Suela Vukcaj, et al.
World Journal of Urology|March 13, 2019
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter studyLuca Triggiani, Rosario Mazzola, Stefano Maria Magrini, et al.
BJR Open|March 25, 2024
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trialMarco Lorenzo Bonù, Alessandro Magli, Davide Tomasini, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Stem Cell Reports|August 5, 2022
Dual inhibition of MAPK and PI3K/AKT pathways enhances maturation of human iPSC-derived cardiomyocytesBayardo I Garay, Sophie Givens, Phablo Abreu, et al.
Acta Oncologica (Stockholm, Sweden)|October 6, 2023
Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivorsSofia Spampinato, Tiziana Rancati, Justyna Magdalena Waskiewicz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 27, 2021
Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort studyAndrea Bresolin, Adriana Faiella, Elisabetta Garibaldi, et al.
Stem Cell Reports|January 11, 2023
Dual inhibition of MAPK and PI3K/AKT pathways enhances maturation of human iPSC-derived cardiomyocytesBayardo I Garay, Sophie Givens, Phablo Abreu, et al.
European Urology Oncology|December 16, 2025
Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation TherapyFederico Mastroleo, Riccardo Villa, Mattia Zaffaroni, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 2024
Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiationGiuseppe Sanguineti, Maddalena Pavarini, Fernando Munoz, et al.
European Urology|June 24, 2023
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter StudyFelix Preisser, Raisa S Abrams-Pompe, Piter Jan Stelwagen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 4, 2025
Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrenceFederica Ferrario, Ciro Franzese, Suela Vukcaj, et al.
World Journal of Urology|March 13, 2019
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter studyLuca Triggiani, Rosario Mazzola, Stefano Maria Magrini, et al.
BJR Open|March 25, 2024
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trialMarco Lorenzo Bonù, Alessandro Magli, Davide Tomasini, et al.
Pageof 9